^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    enristomig (INBRX-105)

    i
    Other names: INBRX 105, INBRX-105, ES-101, INBRX105, ES101, ES 101
    Associations

    News

    Trials
    Company:
    Elpiscience, Inhibrx Biosci
    Drug class:
    CD137 agonist, PD-L1 antagonist
    Related drugs:
    Associations

    News

    Trials
    26d
    Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer (clinicaltrials.gov)
    P1, N=160, Terminated, Inhibrx Biosciences, Inc | Trial completion date: Dec 2025 --> Oct 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Aug 2025 --> Oct 2024; Program terminated due to lack of meaningful efficacy signal.
    Trial completion date • Trial termination • Trial primary completion date • Combination therapy • Metastases
    |
    TMB (Tumor Mutational Burden)
    |
    TMB-H
    |
    Keytruda (pembrolizumab) • enristomig (INBRX-105)
    3ms
    Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer (clinicaltrials.gov)
    P1, N=160, Active, not recruiting, Inhibrx Biosciences, Inc | Phase classification: P2 --> P1 | N=300 --> 160
    Phase classification • Enrollment change • Combination therapy • Metastases
    |
    TMB (Tumor Mutational Burden)
    |
    Keytruda (pembrolizumab) • enristomig (INBRX-105)
    4ms
    Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer (clinicaltrials.gov)
    P2, N=300, Active, not recruiting, Inhibrx Biosciences, Inc | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy • Metastases
    |
    TMB (Tumor Mutational Burden)
    |
    Keytruda (pembrolizumab) • enristomig (INBRX-105)
    over1year
    Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer (clinicaltrials.gov)
    P2, N=300, Recruiting, Inhibrx, Inc. | Phase classification: P1 --> P2
    Phase classification • Combination therapy • Metastases
    |
    TMB (Tumor Mutational Burden)
    |
    TMB-H
    |
    Keytruda (pembrolizumab) • enristomig (INBRX-105)
    almost2years
    Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors (clinicaltrials.gov)
    P1, N=300, Recruiting, Inhibrx, Inc. | N=170 --> 300 | Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Aug 2023 --> Aug 2025
    Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    TMB (Tumor Mutational Burden)
    |
    TMB-H
    |
    Keytruda (pembrolizumab) • enristomig (INBRX-105)
    over2years
    A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=22, Terminated, Elpiscience Biopharma, Ltd. | N=180 --> 22 | Recruiting --> Terminated | Trial primary completion date: Nov 2021 --> Apr 2022; Sponsor's clinical development strategy adjustment
    Enrollment change • Trial termination • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    enristomig (INBRX-105)
    over2years
    A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Malignant Thoracic Tumors (clinicaltrials.gov)
    P1b/2, N=0, Withdrawn, Elpiscience Biopharma, Ltd. | N=276 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 expression • ALK rearrangement
    |
    enristomig (INBRX-105)
    almost3years
    Study of INBRX-105 in Patients With Solid Tumors (clinicaltrials.gov)
    P1, N=170, Recruiting, Inhibrx, Inc. | Trial completion date: Mar 2023 --> Dec 2023 | Trial primary completion date: Nov 2022 --> Aug 2023
    Trial completion date • Trial primary completion date • Combination therapy
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK rearrangement
    |
    Keytruda (pembrolizumab) • enristomig (INBRX-105)
    3years
    Key pharmacokinetic and pharmacodynamic parameters that correlate with the anti-tumor activity of a bispecific PD-L1 conditional 4-1BB agonist (SITC 2021)
    Early efforts to develop 4-1BB targeted agonists were limited by poor tolerability (Urelumab) or insufficient efficacy (Utomilumab). INBRX-105 is currently being evaluated in patients with advanced solid tumors in a first-in-human trial (NCT03809624). Trial Registration INBRX-105 is currently being evaluated in patients with advanced solid tumors in a first-in-human trial (NCT03809624).
    PK/PD data • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8)
    |
    PD-L1 expression
    |
    utomilumab (PF-05082566) • enristomig (INBRX-105) • urelumab (BMS-663513)
    over3years
    Study of INBRX-105 in Patients With Solid Tumors (clinicaltrials.gov)
    P1, N=170, Recruiting, Inhibrx, Inc. | N=90 --> 170 | Trial completion date: Dec 2021 --> Mar 2023 | Trial primary completion date: Jul 2021 --> Nov 2022
    Clinical • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK rearrangement
    |
    Keytruda (pembrolizumab) • enristomig (INBRX-105)